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Abstract 
The growth hormone and appetite are regulated by a 28-peptide hormone called ghrelin, which is 
produced in the stomach, pituitary gland, and other body tissues. The physiological roles fulfilled 
by ghrelin include regulation of food intake, cardiac output, reproductive system, proliferation of 
cells, and formation of osteoblasts, as well as action against inflammation/fibrosis. The ghrelin 
present in the body can be distinguished as acylated ghrelin and deacylated ghrelin. Furthermore, 
both in humans and other animals, the entirety of the gastrointestinal tract comprises ghrelin 
cells, which are classified as open-type and closed-type cells. The present study reviews the 
evidence about how ghrelin cells are distributed in the human and the animal body. 
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OVERVIEW 
The discovery of ghrelin as an endogenous ligand for the growth hormone secretagogue 
receptor (GHS-R) in the stomach was made in 1999. Since then, ghrelin has been found to be 
involved in growth hormone (GH) secretion, dietary intake, glucose metabolism, memory, and 
effects against depression [1, 2]. 
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Ghrelin is mainly produced in the upper part of the stomach, which is called the fundus. 
Ghrelin remains available in a proportion of 35-45% following a complete gastrectomy [3-5]. Its 
action on the body is related to its close association with the GH secretagogue subtype 1a (GHS-
R1a), a G protein-coupled receptor [6]. A large number of tissues and organs, including the 
peripheral and central nervous systems, have high expression of both ghrelin and GHS-R1a. 
Thus, additional organs support ghrelin production, even though the stomach is the primary 
producer. Among the organs that have been found to have ghrelin gene expression in both 
humans and rodents at various developmental stages are the intestine [7], brain [8], heart [9], lung 
[10], testis [11], immune cells [12], and pancreas [13]. 
Research has uncovered that ghrelin and GHS-R1a fulfil key bioactions in a wide range of 
physiological processes, including regulation and homeostasis of central food intake [13], 
modulation of the cardiovascular system [15], gastric acid production and circulation 
improvement [16], as well as regulation of cell proliferation and survival [17]. 
Ghrelin cells have maximum prevalence in the gastric body mucosa, but this prevalence 
decreases in the gastric antrum and in the small intestine, especially in rodents. In adult bodies, 
ghrelin is produced chiefly by the stomach, so other sources have not been closely investigated. 
For instance, studies on rodents have not considered other sources of ghrelin production, 
choosing to focus on the stomach fundus. However, it has been reported that 20% of circulating 
ghrelin was still available in rodents following fundectomy [13]. 
 
GHRELIN HISTORY AND CHARACTERISTICS 
The discovery of peptide derivatives mediating GH secretion from the anterior pituitary 
was made by Cyril Bowers and Frank Momany towards the end of the 1970s [20, 21]. The 
formation of the discovered growth hormone-released peptides (GHRPs) was found to be based 
on chemical alteration of met-enkephalin, including GHRP-6 and GHRP-2 [22]. In a 1996 study, 
GHS and GHRP were used as agonists by Roy Smith and Lex van der Ploeg to assess the GHS 
candidate MK0677 for the GHS-R1a clone [23]. This sparked methodical investigations with the 
purpose of categorising the endogenous GHSR1 ligand. It was only with the discovery of the 
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GHSR1 cognate agonist in 1999 that the ligand became effective. The name “ghrelin” was given 
to the hormone consisting of 28 peptides that was isolated from rodent gastric extracts [24]. In 
2000, it was found that ghrelin was responsible for regulation of weight and intake of fat and 
glucose by acting on the cerebral tissue [25]. 
Derived from the root “ghre” of proto-Indo-European origin, the term “ghrelin” reflects 
its function as a GH peptide. Interestingly, “ghre” and “lin” are widely accepted in hormone 
terminology [28, 29]. 
 
THE PROCESS OF GHRELIN DEVELOPMENT 
To reach full development, ghrelin goes through a number of post-transitional 
modifications. It undergoes translation as preproghrelin, a precursor protein with 117 amino 
acids. This is followed by cleavage of the N-terminal signal co-translation to generate 94 amino 
acids and transfer to the endoplasmic reticulum lumen proghrelin comprising 23 amino acids and 
66AA carboxyterminal peptide known as C-ghrelin (Figure 1). By binding to fatty acyl group (o-
ctanoyl), proghrelin undergoes octanoylation to serine residue (Ser3), which is the third amino 
acid related to the enzyme known as ghrelin O-acyltransferase (GOAT). A ghrelin acylation 
enzyme, GOAT serves to highlight how important acyl modelling is for ghrelin physiology. 
Switch is of particular significance in octanoylation and, to a lesser extent, to the ghrelin effect on 
systemic metabolism. Clear evidence regarding the central function of GOAT in activating 
ghrelin has been brought forth [26, 27]. The formation of mature ghrelin results from packaging 
proghrelin into secretory vesicles and alteration by protein convertase enzymes. Consisting of 28 
amino acids, mature ghrelin is released into the circulation [30]. Conversely, if proghrelin is 
cleaved at the C-terminal (C-ghrelin), it can yield obestatin with 23 amino acids and opposite role 
to ghrelin [35]. 
The stomach-derived human ghrelin gene is present on the third chromosome (3p25-26) 
and consists of five exons and four introns. It secretes various bioactive molecules, including two 
types of ghrelin, namely, acylated ghrelin (AG) and deacylated ghrelin (DAG), as illustrated in 
Figure 1 [16]. In mammalian bodies, the stomach is the producer of AG [31]. 
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In the human body, AG, DAG, and C-ghrelin are the forms of ghrelin found in the bloodstream 
[33-35]. GOAT undertakes acylation of the AG peptide, with expression restricted chiefly to the 
gut, stomach, and pancreas. Hydrolysis causes the loss of the N-acyl group from DAG [26]. 
Meanwhile, C-ghrelin comprises the entire obestatin coding area and may undergo cleavage for 
secretion of peptides, including obestatin [35]. 
In general, AG in the bloodstream is less than 10%, while DAG and C-ghrelin in the 
human bloodstream account for over 90% of the total ghrelin in the bloodstream [32].  
When the gastric mucosa is surgically extracted, there is a reduction of around 80% in the 
synthesis of C-ghrelin in rats [36] and in humans [5]. Understanding is yet to be achieved as to 
whether the same or similar secretory pathways release ghrelin and DAG into the circulation. In 
rats, gastric ghrelin is broken down via deacylation and N-terminal proteolysis [37], with 
deacylation being undertaken by lysophospholipase I [38]. In rats, receptor activity is not 
exhibited by DAG against GHS-R1a, GH release or other endocrine events. Another compound 
demonstrating bioaction is unesterified GHRL, the activity of which is underpinned by a GHS-R 
other than GHS-R1a [31, 39]. 
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Figure 1. Schematic representation of the process of ghrelin maturation, starting with the 
structure of the human ghrelin gene to its active peptide. 
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MORPHOLOGICAL CHARACTERISATION OF GHRELIN CELLS IN THE 
GASTROINTESTINAL TRACT 
In earlier studies, gastric ghrelin was characterised as deriving from an ultra-structured, 
“hormonal-less” A-like cell present in rat pancreas and human P/D1 cells. In the rodent 
gastrointestinal tract (GIT), oxyntic mucosa has the greatest prevalence of ghrelin cells, followed 
by the gastric antrum and small intestine [40-42]. In adult individuals, ghrelin is primarily 
produced by the stomach, so the other hormone sources have been studied to a lesser extent. The 
stomach fundus has been particularly extensively explored in studies on rodents. The ghrelin in 
the rodent bloodstream post-fundectomy has been reported to be at a level of 20% [40], reflecting 
the fact that there are other sources of the hormone besides the stomach, such as the pancreas and 
intestines [13]. The presence of ghrelin-containing X cells in rodent stomach has been indicated 
through immunohistochemistry, immunoelectron-based microscopy, and hybridisation [42, 44]. 
In rodents, ghrelin cells have been found throughout the GIT apart from the myenteric 
plexus, with the stomach body and upper part displaying the greatest production of ghrelin cells. 
Meanwhile, in the large and small intestines, ghrelin cells are found in the epithelium of crypts 
and villi, but these cells are less dense in the large intestine [45, 46]. 
Most ghrelin entero-endocrine cells are classified as closed-type cells because they are not 
continuous to the gastrointestinal lumen. By contrast, ghrelin cells continuous to the 
gastrointestinal lumen are classified as open-type cells and are most prevalent in the stomach 
[47]. 
In terms of histology, there are clear differences between the ghrelin cells in the stomach 
and those in the intestinal tract. The stomach contains spherical cells of small size known as 
closed-type cells [19, 48, 49], while the small intestine and colon contain both closed-type cells 
with a pyramidal or expanded shape and open-type lumen cells that have more than one 
cytoplasmic process and are located in the apical cell membrane (Figure 2). 
 
7 
 
 
Figure 2. Schematic illustration of the two types of ghrelin cells. (A) closed-type ghrelin cells 
delineated in green colour; on the superior part, the cells are sealed by epithelial cells so there is 
no direct interaction with the lumen; when neurons are stimulated, ghrelin is released, as 
indicated by the grey colour, and the cell basal area gives rise to nutrient receptors, as indicated 
by the blue colour. (B) Open-type ghrelin cells delineated in green colour; these cells 
communicate directly with the lumen on their superior part, while the inferior part gives rise to 
nutrient receptors, shown in blue colour. The small orange dots in both types of cells indicate the 
spread of ghrelin to lamina propria, from which it permeates the gastric capillaries and finally the 
systemic circulation. 
 
The regulation of the open-type cells is mechanical, based on luminous signals (e.g. pH, 
nutrients), while the regulation of the closed-type cells is based either on mechanical effect or the 
effect of additional hormones released into the circulation from the GIT (e.g. leptin, somatostatin, 
glucagon) [50, 51]. One study on rainbow trout discovered that the distribution of ghrelin cells in 
the stomach mucosa encompassed both closed-type and open-type cells [52]. Furthermore, 
research employing electron microscopy has revealed that spherical and dense granules of gastric 
mucosal cells exhibited the ghrelin immunogold mark [42, 53, 54]. Ghrelin cells have somewhat 
small and round secretory granules, with varying electron density in their cores, from solid to 
rather electron-lucent. Consequently, the limiting membrane adheres closely to the dense core in 
the majority of granules. In the foetus, there is no difficulty differentiating ghrelin cells from β 
cells based on the thick uneven structure of their granules [13]. Meanwhile, on a study on 
rodents, hamsters were shown to have significantly smaller ghrelin granule diameters (200,8 ± 
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8,8 nm) compared to mice (277,7 ±11.1 nm) and rats (268,8 ± 13,0 nm) [55]. There were no 
major differences in ghrelin-immunoreactive cells between mice and humans (147 ± 30 nm); 
however, by comparison to rats and humans, dogs displayed considerably larger ghrelin cell 
granules (183 ± 37 nm vs 273 ± 49 nm). Ultrastructure studies have characterised ghrelin cells as 
well-defined spherical, compact-to-thin, haloed secretory cells around 140-nm in width, located 
in the core of the oxyntic gland, and presenting X/A-like granules. In the stomach, ghrelin cells 
can be found in the proximity of cells that secrete histamine. In dogs, ghrelin cells are typically 
spherical and associated with a range of sizable, solid, electron-dense X-like granules of oval 
shape with significant marking for ghrelin antibodies [56]. 
Positive ghrelin cells are likely to be assimilated in the plasma instead of the intestinal 
tract because they are found close to capillaries and do not have contact with the oxyntic gland 
lumen [28]. Table 1 provides an overview of the GIT location of cells that secrete ghrelin. 
 
Table 1. The distribution of ghrelin cells in humans and other animals, listed alphabetically 
 
Site of ghrelin cells 
Morphology of the ghrelin 
cells 
Reference 
Amphibians 
and reptiles 
Stomach (mucosal layer) 
not in myenteric plexuses 
and muscle layer 
Closed cell type [60], [61] 
Canine Stomach Closed and open types [42] 
Chicken 
First part of the stomach 
(middle layer of mucosal 
layer) 
Closed cell type [59] 
Dog Stomach Closed and open types [42] 
Human 
Stomach (all parts of the 
fundic gland) 
Open and closed cell types [56] 
Mice gastric fundus Closed and open types [58] 
Pigs From stomach to cecum Closed and open types [51] 
Rainbow 
trout 
Stomach (mucosal layer) Closed and open types [2] 
Rats 
Stomach (from base to 
body of fundic gland) 
Closed type only or both 
types   
[2], [57] 
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GHRELIN CELL DISTRIBUTION IN HUMANS AND ANIMALS 
Distribution of ghrelin cells in the human GIT 
Gastrectomy is an intervention performed in cases of cancer or perforated ulcer, involving 
removal of the stomach, either partially or entirely. One study concluded that the stomach was the 
main source of ghrelin in the bloodstream since patients who had undergone complete 
gastrectomy exhibited a 65% reduction in plasma-like immune rates [5]. Similarly, a different 
study reported that the levels of immunoreactive ghrelin in plasma were almost halved in the 
aftermath of complete gastrectomy compared to pre-gastrectomy; however, there was a 
subsequent progressive rise in the plasma ghrelin levels, suggesting that other sources of ghrelin 
offset the ghrelin lost through stomach removal [68]. 
A sex-based difference in the distribution of ghrelin cells and levels of ghrelin in plasma 
has been discovered, with the plasma ghrelin levels being higher in females than in males [65]. 
It has also been proposed that, in humans, the levels of ghrelin in the bloodstream were 
regulated by sex hormones, since testosterone therapy was observed to enhance ghrelin levels in 
hypogonadal patients [69]. The regulatory effect of sex hormones was reinforced by the 
observation that there was a higher number of ghrelin cells with expression of the oestrogen α-
receptor three days post-ovariectomy [70]. 
Anti-ghrelin antibody was employed by Tanaka-Shintani and Watanabe to analyse how 
immunoreactive ghrelin cells were distributed in the gastric mucosa in humans, with results 
revealing that those cells were mainly located in the stomach fundus and there was a close 
correlation between their distribution and the distribution of parietal cells. The overall cell 
number for rich and mild types was 3.70 ± 3.31 and 1.18 ± 2.67, respectively, for every area of 
the fundus. The area of the duodenum also contained immunoreactive ghrelin cells, although not 
in such a great abundance as the stomach [71]. 
Other studies reported that the intestine had the greatest concentration of immunoreactive 
ghrelin cells, with lower concentrations in the duodenum, jejunum, and ileum, and absence in the 
colon. The majority of the ghrelin cells were present in the Lieberkühn crypts [47, 62]. 
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Obese females have been observed to have a greater abundance of ghrelin cells than obese 
males (p > 0.05). The stomach body had the greatest concentration of ghrelin cells, followed by 
the fundus and antrum. By contrast, patients with H. pylori infection or gastritis were found to 
have a lower abundance of ghrelin cells [67]. 
A study that investigated how the levels of ghrelin in serum, the number of ghrelin cells, 
and weight were correlated in patients with Prader-Willi syndrome reported that the stomach 
fundus contained a number of ghrelin cells that was 2-3 times higher, while the levels of ghrelin 
in plasma were also abnormally high, even in younger patients [66]. 
In the context of embryonic development, ghrelin cells appear in the foetal stomach from 
day 18, proliferating in direct proportion with foetal growth. During the first week of embryonic 
development, positive-immunostained ghrelin cells emerged at the base of the gland, while in the 
third week, they emerged at the base and neck, achieving distribution from the base to the neck of 
the fundic gland during post-neonatal development [57]. In a different study, the number of 
immunoreactive ghrelin cells was low at day 21 of embryonic development, but grew 
progressively afterwards and then declined [63]. Furthermore, it has been suggested that the 
increase in the levels of gastric ghrelin mRNA by age was correlated with the rise in the number 
of ghrelin cells [64]. 
In humans, another organ associated with the presence of immunoreactive ghrelin cells is 
the pancreas. The cells secreting α glucagon and β insulin and the δ-cells in pancreatic islets have 
endogenous expression of ghrelin, whilst the pancreatic α and β cells have preponderant 
expression of GSH-R1a [99, 100]. Furthermore, it has been discovered that, by comparison to the 
adult pancreas, the foetal and neonatal pancreas has a higher number of ghrelin cells. 
Evidence has been produced regarding the consistent lack of hormone related to immunoreactive 
ghrelin cells in the common islet-type of cells, namely, α, β, δ, and pancreatic polypeptide cells 
(PP-cells) based on double or triple immunostaining for ghrelin and four major islet hormones 
(i.e. glucagon, insulin, somatostatin, and PP-cells) [113]. Ghrelin cells have also been found in 
foetal and neonatal rat pancreas [114, 116] and in mouse pancreas [117, 118]. Furthermore, from 
day 8 of mouse embryonic development, ghrelin cells start to participate in the formation of 
Langerhans islets. The pancreas secretes ghrelin on a constant basis during embryonic 
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development, but the release rate decreases rapidly after birth. In humans, only a particular group 
of cells has ghrelin expression in islets; by contrast, in mice, a subset of ε-cells is chiefly 
responsible for the glucagon-based production of ghrelin in islets [120]. 
 The insulin produced by the pancreatic β cells undertakes modulation of glucose homeostasis. 
The involvement of ghrelin in glucose homeostasis has been highlighted by a number of studies 
and it is presumed that, in humans, ghrelin has an effect on how this process is modulated [41]. 
Ghrelin and GHS-R1a may have a stimulating effect on the functions of the pancreas, as the 
receptor has been found to be present in islands [119]. Furthermore, there is evidence that ghrelin 
and insulin have a reciprocal effect on the modulation of their production [41]. 
 
Distribution of ghrelin cells in rat GIT 
In one study, anti-acylated rat ghrelin antiserum was employed to histologically 
characterise rat ghrelin cells and determine how they were distributed. It was observed that the 
distribution of ghrelin cells spanned the whole rat gastrointestinal mucosa, from the stomach to 
the colon. Moreover, both closed-type and open-type of cells were distinguished, as well as both 
types of ghrelin, with DAG being present mainly in the perinucleus region and AG occurring at 
the edges of the cytoplasm [19]. 
Morphometric analysis revealed that the greatest concentration of ghrelin cells was in the 
rat stomach, followed by the duodenum, with reduced concentration in the large and small 
intestines [72]. Sex-based differences ghrelin cell presence in rats have also been reported, with 
female rats displaying a higher number of ghrelin cells and from an earlier developmental stage 
[73]. 
In [47], Wistar rats were employed to determine whether it was possible to offset the 
ghrelin lost due to gastrectomy by increasing the presence of ghrelin cells in the duodenum. To 
that end, the rats were subjected to sleeve gastrectomy followed by reoperation 30-60 days later. 
The latter,involved dissection of a duodenal segment for the purposes of immunohistochemistry 
to determine the number of ghrelin cells. Results indicated a proliferation of immunopositive 
ghrelin cells in the duodenum, which was considered to be unrelated to the sleeve gastrectomy. 
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In [74], a gradual rise in the levels of mRNA gastric ghrelin was observed during the 
second and third weeks post-partum. Similarly, in [75], the levels of gastric ghrelin increased 
constantly up to three months post-partum. Another study reported that the gastric and intestinal 
tract contained both open- and closed-type of ghrelin cells, with the stomach having the greatest 
concentration of ghrelin cells, while the number of open-type cells increased steadily from the 
stomach to the lower intestine. In addition, rats of both sexes exhibited positive ghrelin cells in 
the stomach immediately post-partum, with a steady rise in the level of expression of gastric 
ghrelin up to two months of age after birth [72]. 
In [76], the use of immunohistochemistry and immunoelectron microscopy to investigate 
ghrelin cell distribution in the stomach of Wistar rats revealed that immunoreactive positive 
ghrelin cells spanned the area from the fundic gland neck region to the actual fundus glands. 
Furthermore, the granules of enteroendocrine type X cells were discovered via ultrastructural 
analysis to have positive-immunolabelled ghrelin cells. 
Immunohistochemistry was also the approach adopted in [73] to identify ghrelin-positive 
mast cells and establish where they were found and how they were distributed. Results showed 
that ghrelin was produced by the mast cell granules, which were smaller than tryptase-positive 
mast cells. Thus, it was confirmed that mast cell granules present in rodent stomach wall 
contained ghrelin, implying that mast cells were an important ghrelin source. 
 
Distribution of ghrelin cells in mouse GIT 
The preferred animal model for developmental studies on gene modulation is the mouse. 
From the fact that appetite is stimulated by ghrelin in both rodents and humans, it has been 
deduced that the hormone represents an orexigenic antipode to anorexigenic leptin, anticipating 
that appetite suppression and weight loss could be achieved through pharmacologic ghrelin 
activation [58, 77]. However, this theory has not been supported by investigations of ghrelin on 
mouse models, which did not exhibit significant appetite suppression or weight loss [27, 78-80]. 
On the other hand, it has been observed that mice with ghrelin deficiency do not have an 
abnormal body weight or dietary intake, and actually, it appears that, in mice, ghrelin serves 
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primarily to regulate glucose in the blood. Several studies have reported that tolerance to glucose 
is enhanced by ghrelin ablation by stimulating elevated production of insulin [81, 82]. Similar to 
mice with ghrelin deficiency, mice with GHSR deficiency do not gain weight when given a diet 
rich in fat. Some studies have argued that, to some extent, this might be due to the fact that such 
mice have a moderate pituitary and use fat selectively for energy purposes [83, 84]. In [85], it 
was found that mice with ghrelin deficiency and of different origins displayed reduced body 
weight and fat mass, which was tentatively attributed to intensified energy use and movement. 
Furthermore, studies on mouse models with ghrelin knockout concluded that dietary intake or 
development did not depend critically on the ghrelin peptide [78], and mice with ghrelin 
knockout did not eat less or were of smaller size, but they did differ from wild counterparts in 
terms of their behavioural phenotype related to dietary intake [58, 78]. 
 
Ghrelin cell distribution in non-mammalian vertebrates 
A number of vertebrates have been identified to have ghrelin cells [86, 87], with 
evolutionary highly conserved ghrelin N-terminal areas. One study has been successful in 
isolating ghrelin from trout, revealing that octanoic or decanoic acid modified the third residue of 
ghrelin serine [88]. A different study has detected immunopositive ghrelin cells throughout the 
GIT, but with a gradual reduction in number from the stomach to the duodenum, ileum, cecum, 
and colon [67]. 
In [76], hamsters were used to show that the ghrelin cells were the same as the X cells of 
proper gastric glands and those cells were fewer than in rats and mice. Meanwhile, in [89], 
similarities were reported between ghrelin cells in mammals or birds and ghrelin cells in 
amphibians and reptiles; ghrelin cells were present on the stomach mucosal layer but absent on 
the mesenteric nerve plexus or stomach muscularis externa. 
In birds, immunopositive ghrelin cells have been detected in the proventriculus mucous 
layer, which is the first area of the stomach fundic gland, where digestion enzymes act on the 
food intake alongside the gizzard. On the other hand, immunoreactive ghrelin cells have been 
found to be absent from the avian mesenteric plexus; compared to the mucosal layer, a higher 
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number of immunopositive cells has been identified in the middle layer and the majority of 
ghrelin cells were closed-type cells [90]. 
In [91], the nutraceutical properties of a diet of Spirulina (Arthrospira platensis) were 
investigated by analysing the expression of oligopeptide transporter 1 (PepT1) and ghrelin in the 
GIT of zebrafish (Danio rerio). After two days of fasting, ghrelin began to be secreted and its 
levels increased after five days, initially in the stomach and then in the rest of the GIT. It was thus 
concluded that, in the context of fasting and feeding, the effect of ghrelin on zebrafish was 
opposite that of PepT1 [91]. 
 
THE ROLE OF GHRELIN AND RELATED RECEPTOR 
A number of physiological processes unfold with the involvement of ghrelin. An 
overview of the key roles performed by ghrelin is provided in Figure 3. 
Belonging to the superfamily of G-protein coupled receptors (GPCR), the ghrelin 
receptor, GHS-R, has seven transmission domains across the helix. In humans, the GHS-R gene 
is made up of two exons and one intron and is located on chromosome 3 (3q26.2) [6]. GHS-R is 
differentiated into GHS-R1A, which is a 366 AA protein with seven transmembrane helix 
domains, and GHS-R1B, which is a 289 AA protein with five transmembrane helix domain [92]. 
In mammals, among the behaviours of greatest complexity is food intake, which is 
controlled by different homeostatic and external factors. A key hormone for food intake 
regulation is ghrelin [93, 94]. In rodents, ghrelin circulation intensifies during feeding before 
reverting to normal levels once fullness is achieved [93, 95]. Weight gain often accompanies 
chronic therapies owing to increase in adiposity [96]. In humans, food intake has been observed 
to increase when peripheral ghrelin was administered. There is also a regular increase and 
reduction in the levels of ghrelin in the human bloodstream, corresponding to the daily intervals 
of food consumptions [97]. 
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Figure 3. The key roles fulfilled by ghrelin in physiological processes. 
 
Research using mouse models has reported that angiogenesis was consistently promoted 
when ghrelin was administered. According to a recently conducted study on rat model of 
cardiopulmonary bypass (CPB), CPB-related inflammatory response, apoptosis, and oxidative 
stress were reduced when ghrelin was administered, while the heart pumping function was 
maintained based on signalling GHS-R1a and Akt [98]. 
Studies on rats have also found that ghrelin and its receptor were associated with 
osteoblast development, with ghrelin being reported to help osteoblasts proliferate and 
differentiate both in vitro and in vivo [16]. The regulatory effect of ghrelin on bone development 
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seems to be underpinned by ghrelin induction of the phosphorylation of adenosine 
monophosphate (AMP) active protein kinase [101]. Despite promoting the growth of human 
osteoblasts, which show exclusive expression of GHS-R1b isoform inactive receptor, it appears 
that ghrelin has no effect on the differentiation of osteoclasts in rats [102]. Such results reflect the 
fact that the influence of ghrelin on bone turnover is not dependent on GHS-R1a. Furthermore, in 
more recent studies, ghrelin has been observed to regulate osteoclastogenesis and bone 
metabolism in an age-based manner by interacting with leptin [103, 104]. 
Mouse models of Parkinson’s Disease (PD) and focal ischaemia/reperfusion have 
indicated that ghrelin-regulated GHS-R1a signals demonstrated protective effects. The 
neurological disorder of PD manifests clinically as recurrent tremor, rigidity, and bradykinesia. A 
recent study on C57BL/6 mice found that GHS-R1a signalling dopaminergic neurons for 
triggering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity were controlled 
by ghrelin [105]. 
Ghrelin signals with GHS-1Ra mediation could potentially participate in adult 
hippocampal neurogenesis as progenitor cells have been found to contain hippocampal GHS-1Ra. 
The results of a recent study on adult mice pointed to the fact that hippocampal neuronal 
progenitor cells activated and differentiated in the sub-granular zone (SGZ) [106]. One study 
even proposed that GHS-R1a signalling could be the basis for a strategy for improving 
dysfunctional learning and memory, since it contributes significantly to the proliferation of adult 
hippocampal progenitor cells and the early differentiation of neurons, which in turn underpin the 
generation of agonists in ghrelin receptors [6]. 
Ghrelin and its receptor have been detected in both rat and human testes [107-109], as 
well as in the organs involved in the human female reproductive system, namely, the ovary, 
hilum, and corporal lutea [110]. Furthermore, by diminishing the differentiation of hypothalamic 
gonadotropin release hormone and increasing hormone luteinisation and production of follicle-
stimulating hormones, ghrelin contributes significantly to the regulation of the hypothalamic-
pituitary-gonadal axis [111]. 
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Another key function attributed to ghrelin is the control of lipid storage by white adipose 
tissue. GH production is frequently stimulated by extensive exposure to ghrelin, leading to an 
expansion in the fat mass. Ghrelin has additionally been observed to improve adipogenesis, 
enzyme action for fat storage, and the levels of triglycerides, whilst decreasing fat usage and 
lipolysis [94]. 
Soon after ghrelin was first identified, one study employed in situ hybridisation and 
immunocytochemistry to determine whether ghrelin could be expressed in the human pancreas 
[112]. Findings suggested that ghrelin had an effect on insulin production, being capable of 
suppressing this production in both humans and rodents, and β-cells mediated the action of 
ghrelin [112]. 
The presence of immunoreactive ghrelin cells throughout the human pancreas has been 
confirmed via immunostaining. More specifically, the α, β, and δ-cells in pancreatic islets have 
been found to have endogenous expression of ghrelin, whilst the α and β cells are the main types 
of pancreatic cells with GSH-R1a expression [99, 100]. Furthermore, the foetal and neonatal 
pancreas seems to have a considerably higher number of ghrelin cells than the adult pancreas. 
Moreover, evidence has been produced that immunoreactive ghrelin cells are never associated 
with hormone in the common α, β, δ, and PP-cells in pancreatic islets, as indicated by double or 
triple immunostaining for ghrelin and the four major islet hormones, namely, glucagon, insulin, 
somatostatin, and PP-cells [113]. Ghrelin cells have been confirmed to contribute to foetal and 
neonatal cellular development in rat pancreas [114-116], whilst also occurring in mouse pancreas 
[117, 118]. 
Ghrelin immunoreactivity has also been reported in Langerhans cell islets, as well as in 
human β cells [119] and human α cells [41]. 
Furthermore, from day 8 of mouse embryonic development, ghrelin cells start to 
participate in the formation of Langerhans islets. The pancreas secretes ghrelin on a constant 
basis during embryonic development, but the release rate decreases rapidly after birth. In humans, 
only a particular group of cells has ghrelin expression in islets; by contrast, in mice, a subset of ε-
cells is chiefly responsible for the glucagon-based production of ghrelin in islets [120]. 
18 
 
GHS-R has been reported to be extensively distributed within the lymphoid system, 
leading to the suggestion that ghrelin and GHS-R ligands could be potential signal modulators 
within the immune and endocrine systems, as well as between the central and peripheral nervous 
systems [121, 122]. Furthermore, human urogenital organs could possibly include nerve-immune 
activity, as deduced from rat model research on ghrelin-positive mast cells in autonomic nerves 
[90]. 
 
CONCLUSIONS 
The stomach is the main source of ghrelin. In terms of cellular types, the stomach and other 
areas of the GIT contain different forms of ghrelin cells, with both open-type and closed-type of 
ghrelin cells being present in the stomach and large and small intestines. The ghrelin cells in the 
stomach are considered to contribute the largest amount of ghrelin in the plasma, whereas the 
large and small intestines contribute a smaller amount. Further research is necessary in order to 
shed more light on the biological and histopathological properties of the ghrelin cells present in 
the large and small intestines.   
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